Heartland

Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts

CONCLUSION: CBD differentially regulated basal pro-inflammatory response and attenuated both LPS-induced cytokine release and NF-κB activity in monocytes, similar to dexamethasone. Thus, CBD has a differential inflammatory response and acts as an anti-inflammatory agent in pro-inflammatory conditions but acts as an antagonist with steroids, overriding the anti-inflammatory potential of steroids when used in combination.

Published

1 year ago

August 23, 2019

Republished by Plato

Introduction: Cannabidiol (CBD) containing products are available in a plethora of flavors in oral, sublingual, and inhalable forms. Immunotoxicological effects of CBD containing liquids were assessed by hypothesizing that CBD regulates oxidative stress and lipopolysaccharide (LPS) induced inflammatory responses in macrophages, epithelial cells, and fibroblasts.

Methods: Epithelial cells (BEAS-2B and NHBE), macrophages (U937), and lung fibroblast cells (HFL-1) were treated with varying CBD concentrations or exposed to CBD aerosols. Generated reactive oxygen species (ROS) and inflammatory mediators were measured. Furthermore, monocytes and epithelial cells were stimulated with LPS in combination with CBD or dexamethasone to understand the anti-inflammatory effects of CBD.

Results: CBD showed differential effects on IL-8 and MCP-1, and acellular and cellular ROS levels. CBD significantly attenuated LPS-induced NF-κB activity, IL-8, and MCP-1 release from macrophages. Cytokine array data depicted a differential cytokine response due to CBD. Inflammatory mediators, IL-8, serpin E1, CXCL1, IL-6, MIF, IFN-γ, MCP-1, RANTES, and TNF-α were induced, whereas MCP-1/CCL2, CCL5, eotaxin, and IL-2 were reduced. CBD and dexamethasone treatments reduced the IL-8 level induced by LPS when the cells were treated individually, but showed antagonistic effects when used in combination via MCPIP (monocytic chemotactic protein-induced protein).

Conclusion: CBD differentially regulated basal pro-inflammatory response and attenuated both LPS-induced cytokine release and NF-κB activity in monocytes, similar to dexamethasone. Thus, CBD has a differential inflammatory response and acts as an anti-inflammatory agent in pro-inflammatory conditions but acts as an antagonist with steroids, overriding the anti-inflammatory potential of steroids when used in combination.

Keywords: CBD; E-cigarette; E-liquid; Lung; Marijuana; Vaping.

Source: https://pubmed.ncbi.nlm.nih.gov/31437494/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1TQbL92JdzYTve0m3OsSoggMby2JyZDVBLRHiDMYZkT1hs6YNQ&fc=20200804223051&ff=20200815071230&v=2.11.5

Related Topics:activity cbd Data heartland marijuana

Up Next

When Terpenes and CBD Interact: Understanding the Entourage Effect

Don't Miss

Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome

Heartland

Newbie q: Is Broad Spectrum worth taking over Isolate?

Published

3 hours ago

October 30, 2020

Republished by Plato

Does the extra substances in Broad spectrum really have any benefit without any THC?

I read the following but I dont know enough yet to agree or not: “You cannot get an entourage effect without THC. You cannot therefore completely extract the THC and call it anything but an isolate. You most certainly cannot claim it gives “the benefits of a full spectrum” because it literally cannot do so. There is no such thing as “broad spectrum.” It’s a nonsense term that companies selling isolates are using to trick you into buying their weakened products.”

What are the thoughts of people, esp. those who’ve tried broad and isolate?

Source: https://www.reddit.com/r/CBD/comments/jkz9ic/newbie_q_is_broad_spectrum_worth_taking_over/

Heartland

HOPE™ Products for Autism Launch in Australia After Earlier US Debuts in Pennsylvania and Louisiana

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) just announced that its proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™are now available by prescription to patients in Australia. The HOPE™ forumations, developed by Zelira and noted autism advocate Erica Daniels, first launched in 2019 in Pennsylvania and this fall in Louisiana. “We have had great success […]

The post HOPE™ Products for Autism Launch in Australia After Earlier US Debuts in Pennsylvania and Louisiana appeared first on Green Market Report.

Published

4 hours ago

October 30, 2020

Republished by Plato

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) just announced that its proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™are now available by prescription to patients in Australia. The HOPE™ forumations, developed by Zelira and noted autism advocate Erica Daniels, first launched in 2019 in Pennsylvania and this fall in Louisiana.

“We have had great success with HOPE™ in the US and are thrilled to be able to offer it to patients as a treatment option through the Therapeutic Goods Administration’s (TGA) Special Access Scheme,” says Osagie Imosogie, Chairman of Zelira Therapuetics. “Zelira is proud of this latest achievement in our mission to bring cannabinoid medicine to patients around the world.”

The HOPE™ cannabinoid medicines were developed to support the needs of patients with Autism Spectrum Disorder (ASD) by Daniels and Zelira Therapeutics, which then licensed the proprietary formulas to Ilera Healthcare in Pennsylvania and Ilera Holistic Healthcare in Louisiana. HOPE™ has since established itself as one of the top selling formulated medicinal cannabis products in Ilera Healthcare’s portfolio.

“Autism families are finally beginning to have access to a truly better alternative than the harsh pharmaceuticals of the past and I am so proud that HOPE is now available in Australia,” says Erica Daniels, founder of Hope Grows for Autism and co-creator of the HOPE forumalations. “What started off as a labor of love to find a way to treat my own son is now helping parents around the world.”

HOPE™ is part of Zelira’s family of revenue generating medicinal cannabis formulations. The products consist of two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting Autism Spectrum Disorder (ASD) as a disease indication.

“Following the success of the HOPE™ launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia,” says Dr. Richard Hopkins, Zelira’s global Managing Director. “This represents another key milestone in our commitment to bring the benefits of HOPE™ to patients in global markets.”

Post Views:
2

Source: https://www.greenmarketreport.com/hope-products-for-autism-launch-in-australia-after-earlier-us-debuts-in-pennsylvania-and-louisiana/?utm_source=rss&utm_medium=rss&utm_campaign=hope-products-for-autism-launch-in-australia-after-earlier-us-debuts-in-pennsylvania-and-louisiana

Heartland

How long till I have a “normal” THC high again after vaping CBD?

Published

4 hours ago

October 30, 2020

Republished by Plato

This week I started vaping CBD to try and cut back on my weed consumption during the week as it was starting to interfere with my college classes. The results have blown me out of the water so far, but I’ve also noticed how dampened my THC highs have become. I’m fine with it during the week as I don’t feel awful waking up after a late night sesh and can get my stuff done, but over the weekend I like to indulge a little more since I’ve cut back so much during the week. About how long does it typically take after pausing CBD consumption (I last vaped around 6 pm yesterday) to feel a full, normal high? I do appreciate the calm nature of the highs when you’re loaded up with CBD but it’s just not as satisfying for me in my free time. Any help appreciated 🙂

Source: https://www.reddit.com/r/CBD/comments/jky9co/how_long_till_i_have_a_normal_thc_high_again/